Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
Essential medicines were made available to more than 150 countries around the world during the pandemic
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Subscribe To Our Newsletter & Stay Updated
